Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

Blood

Volumn 126, Issue 4, 2015, Pages 508-519

  McGirt, Laura Y ^a,b   Jia, Peilin ^b   Baerenwald, Devin A ^b   Duszynski, Robert J ^b   Dahlman, Kimberly B ^c,d   Zic, John A ^b   Zwerner, Jeffrey P ^b   Hucks, Donald ^c   Dave, Utpal ^b   Zhao, Zhongming ^b,d   Eischen, Christine M ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL DEATH; CELL FATE; CELL SURVIVAL; CLINICAL ARTICLE; COPY NUMBER VARIATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALE; MYCOSIS FUNGOIDES; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; ULTRAVIOLET RADIATION; WESTERN BLOTTING; DNA SEQUENCE; EXOME; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SKIN NEOPLASMS;

ADULT; AGED; EXOME; FEMALE; FOLLOW-UP STUDIES; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MYCOSIS FUNGOIDES; ONCOGENES; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 84937931145     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-611194     Document Type: Article

References (68)

1. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-866.
2. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32-40.
3. Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides - a disease of antigen persistence. Br J Dermatol. 1974;91(6):607-616.
4. Wohl Y, Tur E. Environmental risk factors for mycosis fungoides. Curr Probl Dermatol. 2007;35:52-64.
5. McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(4):1101-1107.
6. van Kester MS, Ballabio E, Benner MF, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol. 2011;5(3):273-280.
7. Whittaker S. Molecular genetics of cutaneous lymphomas. Ann N Y Acad Sci. 2001;941:39-45.
8. Beyer M, Möbs M, Humme D, Sterry W. Pathogenesis of mycosis fungoides. J Dtsch Dermatol Ges. 2011;9(8):594-598.
9. Karenko L, Hahtola S, Ranki A. Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL). Cytogenet Genome Res. 2007;118(2-4):353-361.
10. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113(1):127-136.
11. Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol. 2010;130(6):1707-1718.
12. Salgado R, Servitje O, Gallardo F, et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol. 2010;130(4):1126-1135.
13. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther. 2011;12(12):1019-1022.
14. Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15(5):787-793.
15. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785-3794.
16. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591-597.
17. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Davé UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood. 2011;118(14):3911-3921.
18. Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009;113(12):2746-2754.
19. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915-919.
20. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398-1403.
21. Clark RA, Chong BF, Mirchandani N, et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol. 2006;126(5):1059-1070.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
23. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
24. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
25. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28(14):1811-1817.
26. Boeva V, Popova T, Bleakley K, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28(3):423-425.
27. Boeva V, Zinovyev A, Bleakley K, et al. Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics. 2011;27(2):268-269.
28. Wang J, Mullighan CG, Easton J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8(8):652-654.
29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
30. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
31. Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics. 2014;7:11.
32. Alexandrov LB, Nik-Zainal S, Wedge DC, et al Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258]. Nature. 2013;500(7463):415-421.
33. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003;22(6):1442-1450.
34. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
35. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013;41(Database issue):D377-D386.
36. Cancer Cell Line Encyclopedia (CCLE). Comprehensive Cell Line Encyclopedia Version 2.17. Cambridge, MA: The Broad Institute; 2014.
37. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125(5):1045-1052.
38. Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res. 2008;14(3):646-653.
39. Yasui DH, Genetta T, Kadesch T, et al. Transcriptional repression of the IL-2 gene in Th cells by ZEB. J Immunol. 1998;160(9):4433-4440.
40. McGregor JM, Crook T, Fraser-Andrews EA, et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol. 1999;112(3):317-321.
41. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107.
42. Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev. 2007;16(2):214-222.
43. Sucheston L, Witonsky DB, Hastings D, et al. Natural selection and functional genetic variation in the p53 pathway. Hum Mol Genet. 2011;20(8):1502-1508.
44. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678-689.
45. Pancewicz J, Nicot C. Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer. 2011;11:502.
46. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553-1565.
47. Witt CM, Hurez V, Swindle CS, Hamada Y, Klug CA. Activated Notch2 potentiates CD8 lineage maturation and promotes the selective development of B1 B cells. Mol Cell Biol. 2003;23(23):8637-8650.
48. Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs. 2013;73(8):857-874.
49. Krishnaswami S, Chow V, Boy M, Wang C, Chan G. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014;54(1):46-52.
50. Huang PH, Chen CH, Chou CC, et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol. 2011;79(1):197-206.
51. Mo R, Rao SM, Zhu YJ. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem. 2006;281(23):15714-15720.
52. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
53. Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev. 2003;17(7):896-911.
54. Shema E, Tirosh I, Aylon Y, et al. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev. 2008;22(19):2664-2676.
55. Kim J, Guermah M, McGinty RK, et al. RAD6-mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell. 2009;137(3):459-471.
56. Mechanic LE, Marrogi AJ, Welsh JA, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis. 2005;26(3):597-604.
57. Bellei B, Cota C, Amantea A, Muscardin L, Picardo M. Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides. Br J Dermatol. 2006;155(6):1223-1229.
58. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-233.
59. Lee SY, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(5):920-926.
60. Fanale D, Iovanna JL, Calvo EL, et al. Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations. Oncology. 2013;85(5):306-311.
61. Krepischi AC, Pearson PL, Rosenberg C. Germline copy number variations and cancer predisposition. Future Oncol. 2012;8(4):441-450.
62. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.
63. Pancewicz J, Taylor JM, Datta A, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010;107(38):16619-16624.
64. Kamstrup MR, Biskup E, Gniadecki R. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach? Br J Dermatol. 2010;163(4):781-788.
65. Eger A, Aigner K, Sonderegger S, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005;24(14):2375-2385.
66. Hidaka T, Nakahata S, Hatakeyama K, et al. Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood. 2008;112(2):383-393.
67. Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol. 1993;29(6):1013-1022.
68. Choi DK, Helenowski I, Hijiya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer. 2014;135(8):1764-1773.